IL17A and psoriasis: Our findings suggest that Iripin-3 offers a unique and targeted mechanism of action through modulation of the IL-23/γδ T/IL-17 axis involved in mannan-induced psoriasis-like inflammation and thus could be a promising therapeutic candidate for treating psoriasis.